AIMProteus
             AKT Inhibitor Miransertib on Proteus Syndrome  - Targeted therapy at NIH
Update:  The AIM Proteus Trial is currently in IRB review status.
Approximate patient enrollment date for trial - Summer 2021

The NIH team is very excited about the opening of this phase 2 clinical trial.

Questions about the NIH AIMProteus trial email here or call. ​